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Abstract 
 
Background 
The causes of phenotypic heterogeneity in familial Alzheimer’s disease with 
autosomal dominant inheritance are not well understood. We assessed data from 
symptomatic individuals with autosomal dominant familial Alzheimer’s disease, with 
the aim of characterising clinical phenotypes and genetic associations with APP and 
PSEN1 mutations.    
 
Methods 
We retrospectively analysed genotypic and phenotype data (age at symptom onset, the 
initial cognitive/behavioural symptoms and the presence of myoclonus, seizures, 
pyramidal signs, extrapyramidal signs, and cerebellar signs.) from all individuals with 
autosomal dominant familial Alzheimer’s disease due to APP and PSEN1 mutations 
studied at the Dementia Research Centre in London. We examined the frequency of 
presenting symptoms and additional neurological features, investigated associations 
with age at symptom onset, APOE genotype and mutation position and explored 
phenotypic differences between APP and PSEN1 mutation carriers. 
 
Findings 
Genetic and phenotypic data was collected from patients between July 1 1987 and 
October 31 2015. Age at onset was recorded for 213 subjects (168 PSEN1, 45 APP), 
detailed history and neurological examination findings for 121 (85 PSEN1, 36 APP). 
Thirty-eight different PSEN1 mutations (four novel) and six APP mutations (one 
novel) were identified. Age at onset depended on mutation, with a younger onset for 
individuals with PSEN1 compared with APP mutations (mean 44 vs 50 years); within 
the PSEN1 group, 79% of age at onset variance was explained by the specific 
mutation. A cluster of five mutations with particularly early onset (mean age at onset 
<40 years) within PSEN1’s first hydrophilic loop suggests high functional importance 
of this region. Whilst all but one of the 36 APP carriers had amnestic presentations, 
atypical cognitive presentations were significantly more frequent (p=0.037) in PSEN1 
carriers, affecting 14 (16%) of 85 subjects. Myoclonus and seizures were the most 
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common additional neurological features; individuals with myoclonus (12/36, 33% of 
APP and 40/85, 47% of PSEN1 carriers) were significantly more likely to develop 
seizures (p=0.036 APP cohort; p=0.001 PSEN1 cohort), which affected around a 
quarter of the subjects in each group (9/36, 25% APP cohort; 20/85, 24% PSEN1 
cohort). The PSEN1 cohort also demonstrated pyramidal (21/85, 25%) extrapyramidal 
(12/85, 14%) and cerebellar (3/85, 4%) signs.  
 
Interpretation  
Autosomal dominant familial Alzheimer’s disease phenotypes are heterogeneous, 
with both age at onset and clinical features being influenced by mutation position as 
well as causative gene. This highlights the importance of considering genetic testing 
in young patients with dementia and additional neurological features, and of 
examining different mutation types separately in future research. 
 
Funding 
Medical Research Council, National Institute for Health Research, Alzheimer’s 
Research UK, Alzheimer’s Society, Guarantors of Brain 
 
 
Introduction  
 
Alzheimer’s disease is the most common cause of dementia and, in a minority of 
individuals, is caused by autosomal dominant mutations in the presenilin 1 (PSEN1),1 
presenilin 2 (PSEN2),2 or amyloid precursor protein (APP) genes.3 Autosomal 
dominant familial Alzheimer’s disease is considered to be clinically similar to 
sporadic disease (with the exception of younger age at onset), and both are 
characterised by progressive impairment of episodic memory. While atypical 
phenotypes are seen in both familial and sporadic Alzheimer’s disease,4-6 relatively 
little is known about the proportion of individuals with autosomal dominant familial 
Alzheimer’s disease who present with atypical cognitive symptoms, the prevalence of 
additional neurological features, or the relationships between genotype and phenotype 
and the pathophysiological mechanisms that may underlie them.  
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Prevention trials for autosomal dominant familial Alzheimer’s disease are underway 
and have stimulated important work investigating biomarker changes in preclinical 
disease. However, they also necessitate better understanding of the natural history of 
the disease in the symptomatic phase and of factors that influence age at onset. A 
recent meta-analysis found that mutation type accounted for a large proportion of the 
variance in age at onset, but substantial variation was still observed between, and even 
within, families with the same mutation.7 Younger ages at onset in APOE4 carriers 
have been reported in some studies analysing families with APP, PSEN1 or PSEN2 
mutations,8-10 although this association was not evident in the recent meta-analysis.7 
Relatively little is known about the factors underlying variability in age at onset 
between different mutations within a single gene, although PSEN1 mutations beyond 
codon 200 have been found to be associated with a later onset, more severe amyloid 
angiopathy and a greater burden of white matter hyperintensities on MRI than 
mutations before codon 200.5,11,12  
 
We aimed to analyse the clinical phenotype (initial cognitive symptoms and the 
frequency of additional neurological features) of a large cohort of individuals with 
autosomal dominant familial Alzheimer’s disease; investigate potential associations 
with age at symptom onset, mutation position, and APOE genotype; and report the 
clinical and neuropathological features of the individuals with novel mutations.  
 
Methods 
 
Participants 
Between July 1, 1987 and October 31, 2015, families with histories suggestive of 
dominantly inherited Alzheimer’s disease were referred to the Dementia Research 
Centre (DRC) at University College London’s Institute of Neurology from clinical 
and research centres across the UK and Ireland. Clinical and genetic data from these 
families (11 with APP mutations, 55 with PSEN1 mutations) were used in this study. 
Five families with APP duplications have also been identified, but were not included 
in the analyses presented here as they have been reported elsewhere.13 Individuals 
with sequence variants of questionable pathogenicity were not included in this study.  
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Contemporaneous records were evaluated (NR) to determine age at symptom onset—
defined as the age at which progressive symptoms of cognitive, behavioural or motor 
change were first noticed by someone who knew the subject well—the initial 
cognitive/behavioural symptoms, and the presence of the following neurological 
features: myoclonus, seizures, pyramidal signs (such as spastic paraparesis), 
extrapyramidal signs (such as rigidity) and cerebellar signs (such as ataxia). 
Neurological features were classified as early (≤5 years from symptom onset) or late 
(>5 years from onset). APOE status was determined by the Medical Research Council 
Prion Unit (London, UK) using minor groove binding probe genotyping assays. 
Ethical approval for the study was obtained from the local institutional ethics 
committee and carried out in accordance with the Declaration of Helsinki; written 
informed consent was obtained from all participants or from their guardian if 
cognitive impairment prohibited written informed consent. 
 
Procedures 
Mutation analysis was carried out as described previously.14 The likely pathogenicity 
of novel variants was predicted using a previously published algorithm,15 and the 
software tools Polyphen (version 1.1.3) and Provean (version 2). Individuals with 
novel variants in PSEN1 or APP were assessed for the presence of additional 
mutations in other dementia-related genes using the Medical Research Council 
(MRC) Dementia Gene Panel.16 See appendix for further details. Where possible, 
when a novel sequence variant was found in the proband, genotyping of other affected 
family members was performed by sequencing the relevant exon to demonstrate co-
segregation between the mutation and disease. 
 
Two individuals with novel variants underwent post-mortem brain donation to the 
Queen Square Brain Bank, UCL Institute of Neurology. Aβ-positive plaque and 
neurofibrillary tangle pathology were assessed using the Consortium to Establish a 
Registry for Alzheimer’s disease recommendations and Braak staging 
respectively.17,18 
 
Statistical analysis 
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Differences in age at symptom onset between the APP and PSEN1 mutation groups, 
and between APOE4 carriers and noncarriers within each genetic group, were 
investigated using two sample t tests. Associations between age at onset and PSEN1 
mutation were analysed using a linear mixed effects model with random effects for 
mutation and family. The intraclass correlation coefficient was used to quantify the 
proportion of variance in age at onset explained by mutation, and by mutation and 
family. Groups of individuals with APP and PSEN1 mutations were analysed 
separately to calculate the proportion of individuals presenting with amnestic 
symptoms; or with atypical symptoms of behavioural change, language impairment, 
dyscalculia or executive impairment; and the proportions with myoclonus, seizures, 
and pyramidal, extrapyramidal or cerebellar signs. Two sample t tests were used to 
investigate whether age at onset differed between those with typical and atypical 
presentations, or those with and without additional neurological features. Fisher’s 
exact tests were used to investigate associations between atypical cognitive 
presentations or additional neurological features and APOE4 status, PSEN1 exon and 
PSEN1 mutation location compared to codon 200. All results are reported as 
statistically significant if p<0.05; analyses were performed using Stata (version 12). 
 
Role of the funding source 
 
The funders of the study had no role in study design, data collection, data analysis, 
data interpretation or writing of the report. The corresponding author had full access 
to all the data in the study and had final responsibility for the decision to submit for 
publication. 
 
 
Results 
 
Information regarding age at symptom onset was available for 213 individuals (168 
with PSEN1 and 45 with APP mutations). APOE status could be established for 126 
of these individuals (95 with a PSEN1 and 31 with APP mutations). Mean (±SD) age 
at onset was significantly later in individuals with APP mutations (50.4 ±5.2, range 
39-59 years, p<0.0001) than in those with PSEN1 mutations (43.6 ±7.2, range 30-62). 
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There was no significant association between possession of an APOE4 allele and age 
at onset in either the PSEN1 (43.6 ±7.2 APOE4 +ve vs. 42.3 ±6.7 APOE4 –ve; 
p=0.385) or APP (50.7 ±4.2 APOE4 +ve versus 50.7 ±5.3 APOE4 –ve; p=0.998) 
cohorts. Table 1 summarises age at onset and type of mutation for the individuals and 
families included in this study, the majority of which had recognised mutations. 
 
In individuals with a PSEN1 mutation, age at onset (table 1) was found to be 
influenced by the specific mutation, with 72% of the variance in age at onset 
explained by mutation (intra-class correlation coefficient, ICC=0.72). Mutation and 
family membership together explained 82% of the variance in age at onset 
(ICC=0.82). Mutations located before codon 200 had, on average, a younger age at 
onset (41.3 ±7.2) than mutations beyond codon 200 (45.8 ±6.4, p<0.0001), which 
appeared to be driven by a younger age at onset for mutations involving exons 5 and 
particularly 4 compared with the later exons (figures 3 & 4). Age at onset for the 
individual with two PSEN1 substitutions (p.Thr291Ala and p.Ala434Thr) was 
excluded as it was unclear whether pathogenicity was due to one or both of these 
amino acid substitutions. The intron 4 (NM_000021.3:c.338+1delG) mutation is 
classified as involving exon 4 as it is located just outside this exon (see appendix for 
further details).19  
 
Detailed contemporaneous records documenting medical history and neurological 
examination findings were available for 121 of 213 individuals (85 with PSEN1 and 
36 with APP mutations), and APOE genotype could be established for 101 of them 
(71 PSEN1, 30 APP). 35 of 36 individuals with APP mutations presented with typical 
amnestic symptoms; the remaining individual presented with dyscalculia but 
developed memory problems soon after. Of the 85 individuals with PSEN1 mutations, 
71 (84%) presented with amnestic symptoms. Atypical cognitive presentations were 
more frequently associated with PSEN1 than APP mutations (p=0.037). Of the 14 
PSEN1 mutation carriers with atypical initial cognitive features, seven (8%) presented 
with behavioural change, three (4%) with language impairment, two (2%) with 
dyscalculia and two (2%) with a dysexecutive syndrome. The PSEN1 subgroup with 
atypical cognitive presentations had, on average, a somewhat later age at onset than 
those with typical amnestic symptoms (46.2 vs 42.0, p=0.046),. Prevalence of atypical 
cognitive presentations differed markedly between exons, occurring in 10 of 22(45%) 
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individuals with exon 8 mutations, and fewer than (20%) of individuals with 
mutations involving other exons (Supplementary Figure 1). As a result, atypical 
presentations were significantly more common in individuals whose mutation was 
located after codon 200 (p=0.006). Individual mutations associated with atypical 
cognitive presentations are listed in Table 2. There was no association between 
atypical cognitive symptoms and APOE4 status. 
 
In the APP group, myoclonus and seizures were the only additional neurological 
features observed. The frequency of myoclonus and seizures did not differ 
significantly between the PSEN1 and APP groups. In the APP group, 12 (33%) of 36 
carriers had myoclonus and nine (25%) of 36 developed seizures. Of the 12 
individuals with myoclonus, onset was early (≤5years from onset) in five (42%), late 
in two (17%), and uncertain in five (42%). Of the nine individuals with seizures, onset 
was early in three, late in three, and uncertain in three. In the PSEN1 group, 40 (47%) 
of 85 carriers had myoclonus and 20 (24%) had seizures. Of the 40 individuals with 
myoclonus, onset was early in 28 (70%), late in nine (23%), and uncertain in three 
(7%). Of the 20 individuals with seizures, onset was early in six (30%), late in 10 
(50%), and uncertain in four (20%). Individuals with myoclonus were significantly 
more likely to develop seizures: 40% developed seizures in the PSEN1 group 
(p=0.001) and 50% in the APP group (p=0.036). There was no association between 
myoclonus or seizures and age at onset or APOE4 status in either the APP or PSEN1 
groups. There was no association between seizures or myoclonus and APOE4 status, 
exon or mutation location with respect to codon 200 in the PSEN1 group. 
 
Pyramidal, extrapyramidal and cerebellar signs were seen in individuals with PSEN1 
mutations (see Table 2 and Supplementary Figure 2). Pyramidal signs were observed 
in 21 (25%) of the 85 PSEN1 carriers. All of these individuals had spastic paraparesis, 
and 18 also had upper limb pyramidal signs. Of the 21 individuals with pyramidal 
signs, 15 (71%) developed them early, although none were reported to have these 
signs before onset of cognitive symptoms. The remaining six (29%) developed them 
late, with an absence of pyramidal signs at earlier assessments. There were no 
associations between pyramidal signs and age at onset or APOE4 status in the PSEN1 
cohort as a whole and insufficient numbers to investigate such associations at the 
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level of individual families or mutations. Pyramidal signs were, however, observed 
more frequently in association with PSEN1 mutations after codon 200 than before 
codon 200 (p=0.024), with particularly high frequency (50%) for mutations on exon 8 
(Supplementary Figure 2).  
 
Extrapyramidal signs were observed in 12 (14%) of the 85 PSEN1 carriers, occurring 
early in eight (67%), late in three (25%), and of uncertain onset in one (8%). No 
associations were found with age at onset, APOE4 status, or exon or PSEN1 mutation 
location compared to codon 200. One of the individuals with early extrapyramidal 
signs (PSEN1 p.Tyr115His), had markedly asymmetrical features consistent with a 
corticobasal syndrome (see appendix). 
 
Cerebellar signs were observed in three (4%) of the 85 PSEN1 carriers, occurring 
early in two, and late in one. No associations were found with age at onset, APOE4 
status, or exon or PSEN1 mutation location compared to codon 200. 
 
Novel variants in APP (p.Thr719Asn, NM_000484.3:c.2156C>A) and PSEN1 
(p.Gln222Pro [NM_000021.3:c.665A>C], p.Phe283Leu [NM_000021.3:c.849T>G]) 
were identified in three individuals with typical amnestic presentations. Two PSEN1 
substitutions (p.Ala434Thr [NM_000021.3:c.1301G>A] and the novel p.Thr291Ala 
[NM_000021.3:c.871A>G] variant) were identified in an individual presenting with 
memory symptoms, Parkinsonism and pyramidal signs, who demonstrated 
Alzheimer’s disease with cotton wool plaques, diffuse deposits and severe amyloid 
angiopathy post-mortem (Figure 1). The final individual with a novel variant (PSEN1 
p.Ser132Ala [NM_000021.3:c.394T>G]), had a dementia with Lewy bodies 
phenotype and demonstrated Alzheimer’s disease with severe neocortical Lewy body 
disease post-mortem (Figure 2). This individual also had an intronic variant 
(NM_005910.5: rs11872014) in the MAPT gene. Although there is no consensus on 
the impact of the variant on MAPT splicing, given that this MAPT variant has been 
found in an elderly healthy control (unpublished data, MRC Prion Unit) and described 
321 times in the Exome Aggregate Consortium (ExAC) dataset 
(http://exac.broadinstitute.org) with an allele frequency of 0.002952 (0.004401 in 
Europeans), it is unlikely to have caused disease in this patient. No additional variants 
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in dementia related genes were found in the other individuals with novel PSEN1 or 
APP variants using the MRC Dementia Gene Panel.16 All novel sequence variants 
identified were absent from 100 healthy, white control patients who were unrelated to 
the affected individuals. With the exception of p.Ser132Ala, which was seen in one 
individual of European ancestry, none of the variants were found in the ExAC dataset. 
See appendix for discussion of the likely pathogenicity of the novel variants and 
further clinical and neuropathological details.   
 
Discussion 
 
This study describes the clinical spectrum of autosomal dominant familial 
Alzheimer’s disease in a large case series from a single UK centre and explores 
factors that may influence phenotypic heterogeneity. Clinically significant phenotypic 
differences were found between PSEN1 and APP mutation carriers, emphasising the 
potential importance of examining these groups separately in observational research 
and clinical trials. In addition to the well known younger age at symptom onset for 
individuals with PSEN1 mutations compared with APP mutations, PSEN1 mutation 
carriers more frequently presented with atypical cognitive symptoms and additional 
neurological features. Behavioural, language, and dysexecutive presentations, spastic 
paraparesis, and other pyramidal, extrapyramidal, and cerebellar signs were only seen 
in the individuals with PSEN1 mutations. Myoclonus and seizures, on the other hand, 
affected a similar proportion of individuals with APP and PSEN1 mutations. In both 
genetic groups, individuals with myoclonus were more likely to develop seizures than 
those without myoclonus, highlighting the importance for clinicians of being vigilant 
for symptoms of seizure activity when myoclonus is present.  
 
Possible limitations of our study were that some atypical phenotypes, such as 
movement disorder presentations or much older onset, may not have been seen in our 
case series due to the ascertainment bias of our centre being more likely to be referred 
younger patients with cognitive symptoms. Also, not all individuals were followed to 
advanced stages of illness, so late neurological features may be more frequent than 
described here. With enrolment of individuals over a long period of time, there is the 
potential for families to have greater awareness and therefore earlier recognition of 
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symptom onset with successive generations.  The relative non-diversity of individuals 
seen in a single country may also limit generalizability of the findings. However, the 
mean age at onset in our cohort was very similar to those reported in a French case 
series,19 and in recent systematic reviews of autosomal dominant familial Alzheimer’s 
disease.5,7,20 As in our case series, spastic paraparesis and extrapyramidal and 
cerebellar signs were seen in French PSEN1, but not APP, mutation carriers, usually 
manifesting within five years of symptom onset. The proportion of French individuals 
with PSEN1 mutations presenting with ‘frontal symptoms’ (11%) was also 
comparable to the combined proportion of individuals in our series whose initial 
cognitive symptoms were behavioural (8%) or dysexecutive (2%). 20 Finally, a non-
amnestic presentation was found in 16% of the autosomal dominant familial 
Alzheimer’s disease cases reported worldwide;5 the same proportion as in the 
individuals with PSEN1 mutations in our cohort.  
 
Whilst a significant minority of the PSEN1 mutation carriers in our study presented 
with non-amnestic cognitive symptoms, all but one of the APP mutation carriers had 
initial memory symptoms. These phenotypic differences have some support from 
neuroimaging studies: we have previously reported APP mutation carriers to have 
greater hippocampal atrophy than PSEN1 carriers of similar disease severity, while 
PSEN1 carriers showed more extensive neocortical atrophy and white matter 
involvement; the latter may underlie some of the atypical features observed in 
PSEN1.21 PSEN1 forms the catalytic subunit of gamma-secretase, which processes 
APP, but also a large number of other substrates involved in various physiological 
functions including myelin repair, vascular and immune function. Gamma-secretase 
carries out an initial endopeptidase cleavage of its substrates followed by successive 
carboxypeptidase-like cleavages. PSEN1 mutations all appear to decrease the 
efficiency of this carboxypeptidase-like activity, resulting in the release of longer A 
peptides, which are more prone to aggregation. Most PSEN1 mutations also affect the 
endopeptidase activity, but to various degrees, potentially impacting on the processing 
of other substrates in addition to APP.22,23 We speculate that altered processing of 
other substrates may contribute to the atypical phenotypes witnessed in association 
with some PSEN1 mutations. Supporting this notion, atypical cognitive presentations 
and pyramidal signs in participants of this study were seen more frequently in 
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association with PSEN1 mutations involving exon 8. The residues encoded by exon 8 
lie within the hydrophilic extended sequence between transmembrane domains six 
and seven of PSEN1, which is where the cleavage site processed by autocatalytic 
activity has been found.24 Furthermore, individuals with two of the most atypical 
phenotypes—corticobasal syndrome (p.Tyr115His)  and dementia with Lewy bodies 
(p.Ser132Ala)  presentations—had mutations involving hydrophilic loop 1, which has 
been proposed to form the initial substrate binding site in PSEN1, with Ser132 
playing a critical role.25 Indeed, the p.Tyr115His mutation has been found to reduce 
endopeptidase efficiency due to substantially decreased affinity for the Notch 
substrate, while the affinity for APP is affected to a lesser extent.22 Certain mutations 
may therefore differentially affect the substrate specificity of the gamma-secretase 
complex and investigating whether this mechanism contributes to atypical clinical 
phenotypes is an important direction for future work. It was notable that the individual 
with the PSEN1 p.Ser132Ala mutation, presenting with a dementia with Lewy bodies 
phenotype, had severe neocortical Lewy body pathology. However, concomitant 
Lewy body pathology is a frequent finding in autosomal dominant familial 
Alzheimer’s disease.26 Large cohort studies will be important to further investigate 
clinical phenotype and clinicopathologic correlations in autosomal dominant familial 
Alzheimer’s disease, ideally with unaffected family members acting as controls. 
 
Our results suggest that multiple factors may contribute to phenotypic heterogeneity 
in autosomal dominant familial Alzheimer’s disease. There was often considerable 
variability in the clinical features of individuals with the same mutation, even within a 
single family. Even so, we found that mutations before codon 200 were associated 
with younger age at onset, and that individuals with seizures tended to have earlier 
symptom onset, whilst mutations beyond codon 200 were more frequently associated 
with later ages at onset, atypical cognitive presentations, and pyramidal signs. Given 
the relatively small numbers of subjects manifesting each atypical feature, and the 
numbers of associations (although not independent), it is important to be cautious 
about nominally significant associations. Nonetheless, we felt it important to report 
them to allow replication in other cohorts. Indeed, a recent systematic review5 also 
found that PSEN1 mutations before codon 200 had younger ages at onset and were 
more frequently associated with seizures and myoclonus, whilst mutations beyond 
codon 200 were more frequently associated with spastic paraparesis. Codon 200 is an  
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arbitrary cut-off, and mapping the mean ages at onset for different mutations to the 
structure of PSEN1 (Figure 4) suggests there may be certain areas of the protein 
where mutations cause particularly early-onset disease, such as the first hydrophilic 
loop encoded by exons four and five. This extracellular loop contributes to a key 
allosteric core that changes A profiles through carboxypeptidase-like activity 
without affecting the endopeptidase function of gamma-secretase.27,28 As qualitative 
changes in A profiles appear to underlie the pathogenicity of PSEN1 mutations,22,23 
one could speculate that they may be more dramatically altered by mutations 
involving this allosteric core, resulting in a more aggressive phenotype.  
 
We have demonstrated that a significant minority of individuals with autosomal 
dominant familial Alzheimer’s disease do not have typical amnestic presentations. As 
atypical presentations also occur in sporadic Alzheimer’s disease, we do not feel that 
our findings challenge the idea that familial cases represent a paradigm for 
Alzheimer’s disease, but rather highlight the importance of distinguishing and 
investigating atypical phenotypes in the endeavour to understand the complex 
underlying mechanisms that may contribute to disease. The clinical features of 
PSEN1-associated familial Alzheimer’s disease may erroneously suggest a diagnosis 
of frontotemporal or vascular dementia, corticobasal degeneration, or dementia with 
Lewy bodies. We suggest that it is important to consider autosomal dominant familial 
Alzheimer’s disease in the differential diagnosis of patients with early-onset dementia 
with additional neurological features. Autosomal dominant familial Alzheimer’s 
disease detection rates have, at least historically, been lower than expected based on 
genetic epidemiology data, and have shown considerable variability across different 
regions of the UK.29 Failure to identify a mutation in these families may deprive the 
affected individual of a correct diagnosis and appropriate symptomatic treatment, and 
also has implications for the individual’s family. Those at risk of autosomal dominant 
familial Alzheimer’s disease should, if they wish, be given access to genetic 
counselling so that they may consider their choices in a variety of areas including 
predictive genetic testing, and reproductive options such as pre-implantation genetic 
diagnosis. They may benefit from the peer support of connecting with other families 
affected by autosomal dominant familial Alzheimer’s disease,30 and from 
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opportunities to participate in research, including preclinical treatment trials aiming to 
delay or prevent the onset of symptoms. 
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Research in context 
 
Evidence before this study 
We searched PubMed for reports on the clinical phenotype of autosomal dominant 
familial Alzheimer’s disease up to April 23, 2016 using the following search terms: 
“familial Alzheimer’s disease”, “autosomal dominant Alzheimer disease”, 
“presenilin”, “PSEN1”, “PSEN2”, “APP”, with no language restrictions. We 
identified 200 publications reporting clinical information on individuals with 
autosomal dominant familial Alzheimer’s disease, mostly from single pedigrees or 
small case series.  
We found 22 reviews of this literature, although the results of such reviews may 
potentially be subject to the publication bias of centres tending to report atypical 
phenotypes more frequently than typical presentations. Therefore, whilst it is clear 
from the literature that atypical phenotypes occur in autosomal dominant familial 
Alzheimer’s disease, less is known about the frequency of their occurrence, 
correlations between genotype and phenotype and the pathophysiological mechanisms 
that may underlie them. 
 
Added value of this study 
The current study investigates the clinical phenotype of autosomal dominant familial 
Alzheimer’s disease in a large UK case series including patient data since 
identification of the first mutation over 25 years ago. We ascertain the frequency of 
presenting cognitive symptoms and additional neurological features, and investigate 
their associations with age at symptom onset, APOE genotype, and mutation position. 
Forty-four different mutations in the PSEN1 or APP genes are represented in the 
cohort, including five novel variants which are reported here for the first time. We 
found clinically important phenotypic differences between subjects with APP and 
PSEN1 mutations. In addition to their well known younger age at symptom onset, 
PSEN1 mutation carriers more frequently presented with atypical cognitive symptoms 
and additional neurological features. Exploration of heterogeneity of clinical 
presentations between different PSEN1 mutations suggested that mutation position 
may have an influence on phenotype. Atypical cognitive presentations and spastic 
paraparesis were associated with PSEN1 mutations beyond codon 200, particularly 
 17 
involving exon 8. Conversely, particularly early ages at onset were observed for a 
cluster of mutations before codon 200 involving PSEN1’s first hydrophilic loop  
 
Implications of all the available evidence 
In describing the wide clinical spectrum of autosomal dominant familial Alzheimer’s 
disease presentation, we highlight the importance for clinicians of considering genetic 
testing in young patients with dementia and additional neurological features, 
particularly when there is a family history or when the family history is censored. 
Appreciation of atypical autosomal dominant familial Alzheimer’s disease phenotypes 
is important from a diagnostic perspective and may also offer insights into the 
variable mechanisms by which different mutations cause disease. In view of the 
phenotypic heterogeneity that exists within autosomal dominant familial Alzheimer’s 
disease, particularly between APP and PSEN1 mutation carriers, it may be 
informative to examine different mutation types separately in the analysis of 
autosomal dominant familial Alzheimer’s disease observational studies and clinical 
trials.  
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Table 1. Mutation cases in the DRC cohort and the mean age at onset for each 
mutation 
 
Gene Mutation Exon Number 
of 
families 
Number of affected 
individuals in 
family (range) 
 
Mean age at 
onset 
(range) 
APP p.Ala692Gly 17 1 3 46 (39-54) 
 p.Val715Ala 17 1 1 42 
 p.Val717Gly 17 1 11 50 (40-59) 
 p.Val717Ile 17 6 22 (1-8) 52 (39-59) 
 p.Val717Leu 17 1 4 49 (48-51) 
 p.Thr719Asn 
 
17 1 1 46 
PSEN1 Intron 4 (g.23024delG) 
p.Tyr115Cys 
p.Tyr115His 
p.Thr116Asn 
p.Glu120Lys 
p.Ser132Ala 
p.Met139Val 
p.Ile143Phe 
p.Met146Ile 
p.Leu153Val 
p.Tyr154Cys 
p.Leu166Arg 
p.Leu166del 
ΔI167 (p.Ile168del) 
p.Leu171Pro 
p.Glu184Asp 
p.Ile202Phe 
p.Gln222Pro 
p.Gly206Val 
p.Ile229Phe 
p.Leu235Val 
p.Phe237Leu 
p.Leu250Ser 
p.Ala260Val 
p.Cys263Phe 
p.Pro264Leu 
p.Pro267Ser 
p.Arg269His 
p.Arg278Ile 
p.Glu280Gly 
p.Phe283Leu 
p.Ser290Cys 
ΔE9* 
p.Arg377Met 
4 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
8 
8 
8 
8 
8 
8 
8 
8 
9 
9 
11 
4 
2 
1 
1 
2 
1 
4 
1 
2 
1 
1 
1 
1 
1 
1 
3 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
1 
3 
1 
3 
1 
1 
1 
1 
17 (1-12) 
2 
4 
2 
7 (2-5) 
3 
18 (1-9) 
2 
6 (2-4) 
3 
1 
1 
1 
5 
5 
5 (1-2) 
2 
1 
1 
3 
4 
1 
7 
1 
2 
3 (1-2) 
2 
4 (1-2) 
7 
16 (1-8) 
15 
5 
1 
1 
38 (35-45) 
39 (34-44) 
34 (30-36) 
34 
35 (31-39) 
59 (58-60) 
40 (35-48) 
56 (53-59) 
48 (43-50) 
35 (35-36) 
41 
40 
38 
54 (43-60) 
42 (40-43) 
40 (37-45) 
48 (47-48) 
45 
30 
33 (32-34) 
52 (44-59) 
47 
52 (47-56) 
40 
59 (58-59) 
50 (44-56) 
38 
55 (50-62) 
51 (44-59) 
42 (39-49) 
46 (42-48) 
42 (41-44) 
45 
38 
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p.Gly378Val 
p.Gly394Val 
p.Pro436Ser 
p.Thr291Ala and 
p.Ala434Thr 
 
11 
11 
12 
9 and 12 
1 
1 
1 
1 
5 
1 
3 
1 
 
44 (41-48) 
40 
46 (44-50) 
42 
 
* The exon 9 deletion (NM_000021.3:c.869-1G>T; p.Ser290Cys;Thr291_Ser319del) 
commonly referred to as ΔE9. 
 
Sex-specific information was not recorded during evaluation of patient medical 
histories 
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Figure 1: Neuropathological findings in a 42 year old man with a PSEN1 double 
substitution, p.Thr291Ala and p.Ala434Thr, presenting with cognitive 
impairment, pyramidal, and extrapyramidal signs 
Amyloid pathology in the hippocampus of (a) cotton wool plaques and (b) capillary 
cerebral amyloid angiopathy (c) Diffuse deposits, shown in the granule cell layer of 
the cerebellum. (d) A deposits in the leptomeningeal blood vessels, (e) and A 
deposits shown to be in an amyloid conformational state using Congo red staining. (f) 
AT8 immunoreactivity for abnormally phosphorylated tau in the CA1 sub-region of 
the hippocampus, (g) and at 40X magnification detailing the neurofibrillary tangles 
and neuropil threads. Bar in a represents 60μm in a, c, d and g; 20μm in b and e and 
200μm in f. 
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Figure 2: Neuropathological findings in a 70 year old man with the novel PSEN1 
p.Ser132Ala mutation presenting with a dementia with Lewy bodies phenotype 
Amyloid pathology in the hippocampus of (a) cored amyloid plaques (double arrows), 
and (b) diffuse A (arrows). (c) AT8 immunoreactivity for abnormally 
phosphorylated tau of neurofibrillary tangles in the CA1 sub-region of the 
hippocampus, and (d) of neuritic plaques in the temporal cortex (arrows). (e) Alpha-
synuclein immunohistochemistry of Lewy neurites and Lewy bodies in the CA1 sub-
region of the hippocampus, and (f) Lewy bodies found in the dopaminergic neurons of 
the substantia nigra (arrows). Bar in a represents 60μm in a, c, d and e; 20μm in f and 
10μm in b. 
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Figure 3. Age at onset for individuals with mutations involving each exon of the 
PSEN1 gene.  
Each dot represents one individual’s age at onset. Within each exon, different colours 
represent separate families; multiple families with the same mutation are indicated by 
different shades of the same colour (blue, green, purple or pink). Bars indicate mean 
age at onset for mutations involving each exon 
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Figure 4. Mean age at onset for the PSEN1 mutations in the cohort, shown by 
quartile according to their location on PSEN1 
Predicted membrane topology of PSEN1, with the nine transmembrane domains (dark 
green shaded boxes) and boundaries between coding exons indicated. The sites of 
amino acid substitution (or insertion in the case of Intron 4, and deletion in the case of 
ΔE9) are indicated by coloured circles, with the colour representing the quartile that 
the mean age at onset for that variant falls within. Red represents the youngest ages at 
onset in the first quartile, yellow the second quartile, green the third quartile, and blue 
the oldest ages at onset in the fourth quartile. Figure adapted from 31. 
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Table 2. Mutations in APP and PSEN1 associated with atypical phenotypes and 
additional neurological features 
 
Phenotype Gene  Mutation Proportion of 
individuals with the 
mutation 
demonstrating the 
phenotype 
Behavioural 
presentation 
 
 
PSEN1 p.Met139Val 
p.Leu166Arg 
p.Pro264Leu 
p.Arg269His 
p.Arg278Ile 
p.Glu280Gly 
 
1/14 
1/1 
2/3 
1/2 
1/5 
1/9 
Language 
presentation 
 
PSEN1 p.Pro264Leu 
p.Arg278Ile 
1/331 
2/532 
Dycalculia 
presentation 
 
 
PSEN1 
 
 
APP 
Intron 4 
(g.23024delG) 
p.Leu235Val 
p.Val717Ile 
1/9 
 
1/2 
1/19 
 
Dysexecutive 
presentation 
 
PSEN1 p.Glu280Gly 2/9 
Myoclonus 
 
PSEN1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APP 
Intron 4 
(g.23024delG) 
p.Tyr115Cys 
p.Tyr115His 
p.Ser132Ala 
p.Met139Val 
 
p.Met146Ile 
p.Glu184Asp 
p.Ile202Phe 
p.Gly206Val 
p.Ile229Phe 
p.Phe237Leu 
p.Leu250Ser 
p.Ala260Val 
p.Pro264Leu 
p.Arg269His 
p.Arg278Ile 
p.Glu280Gly 
p.Ser290Cys 
p.Gly394Val 
p.Val717Gly 
p.Val717Ile 
p.Val717Leu 
6/9 
 
1/1 
1/2 
1/1 
10/1433,34 
 
2/3 
1/3 
1/135 
1/1 
1/1 
1/1 
1/1 
1/1 
1/3 
1/2 
3/5 
4/9 
1/2 
1/1 
5/1136 
5/19 
1/4 
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p.Thr719Asn 
 
1/1 
Seizures 
 
PSEN1 
 
 
 
 
 
 
 
 
 
APP 
Intron 4 
(g.23024delG) 
p.Tyr115Cys 
p.Tyr115His 
p.Met139Val 
 
p.Met146Ile 
p.Gly206Val 
p.Ala260Val 
p.Pro264Leu 
p.Pro267Ser 
p.Glu280Gly 
p.Ala692Gly 
p.Val717Gly 
p.Val717Ile 
p.Val7171Leu 
 
5/9 
 
1/1 
1/4 
4/1433,34 
 
2/3 
1/1 
1/1 
2/3 
1/1 
2/9 
1/1 
5/1136 
2/19 
1/4 
Spastic 
paraparesis 
+/- other 
pyramidal signs 
 
 
PSEN1 Intron 4 
(g.23024delG) 
p.Tyr115His 
p.Glu120Lys 
p.Met139Val 
p.Met146Ile 
p.Leu166Arg 
p.Glu184Asp 
p.Pro264Leu 
p.Arg278Ile 
p.Glu280Gly 
p.Gly394Val 
p.Thr291Ala & 
p.Ala434Thr 
ΔE9 
1/9 
 
1/2 
1/3 
1/14 
1/3 
1/1 
1/3 
1/3 
2/5 
8/937 
1/1 
1/1 
 
1/1 
 
Extrapyramidal 
signs 
 
PSEN1 p.Tyr115His 
p.Glu120Lys 
p.Ser132Ala 
p.Met146Ile 
p.Leu166Arg 
Delta 167 
(p.Ile168del) 
p.Arg278Ile 
p.Glu280Gly 
p.Thr291Ala & 
p.Ala434Thr 
 
1/3 
1/3 
1/1 
1/3 
1/1 
1/2 
 
3/5 
2/9 
1/1 
Cerebellar signs 
 
PSEN1 p.Tyr115Cys 
p.Glu280Gly 
p.Ser290Cys 
1/1 
1/937 
1/2 
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